Literature DB >> 28650537

Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma.

Andrew J Sinnamon1, Madalyn G Neuwirth1, Edmund K Bartlett1, Salman Zaheer1, Mark S Etherington1, Xiaowei Xu2, David E Elder2, Brian J Czerniecki1, Douglas L Fraker1, Giorgos C Karakousis1.   

Abstract

BACKGROUND: Nodal recurrence following negative sentinel lymph node biopsy (SLNB) for melanoma is known as false-negative (FN) SLNB. Risk factors for FN SLNB among patients with trunk and extremity melanoma have not been well-defined.
METHODS: After retrospective review, SLNB procedures were classified FN, true positive (TP; positive SLNB), or true negative (TN; negative SLNB without recurrence). Factors associated with high false negative rate (FNR) and low negative predictive value (NPV) were identified by comparing FNs to TPs and TNs, respectively. Survival was evaluated using Kaplan-Meier methods.
RESULTS: Of 1728 patients, 234 were TP and 37 were FN for overall FNR of 14% and NPV of 97.5%. Age ≥65 years was independently associated with high FNR (FNR 20% in this group). Breslow thickness >1 mm and ulceration were independently associated with low NPV. Among patients with ulcerated tumors >4 mm, NPV was 88%. Median time to recurrence for FNs was 13 months. Among patients with primary melanomas ≤2 mm in depth, overall and distant disease-free survival were significantly shorter with FN SLNB than TP SLNB.
CONCLUSIONS: Older age is associated with increased FNR; patients with thick, ulcerated lesions should be considered for increased nodal surveillance after negative SLNB given low NPV in this group.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  biopsy; false negative; melanoma; sentinel lymph node

Mesh:

Year:  2017        PMID: 28650537     DOI: 10.1002/jso.24743

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma.

Authors:  Richard J Straker; Michael J Carr; Andrew J Sinnamon; Adrienne B Shannon; James Sun; Karenia Landa; Kirsten M Baecher; Christian Wood; Kevin Lynch; Harrison G Bartels; Robyn Panchaud; Michael C Lowe; Craig L Slingluff; Mark J Jameson; Kenneth Tsai; Mark B Faries; Georgia M Beasley; Vernon Sondak; Giorgos C Karakousis; Jonathan S Zager; John T Miura
Journal:  Ann Surg Oncol       Date:  2021-04-22       Impact factor: 5.344

2.  Lymphatic Transport Efficiency Determines Metastatic Potential of Cutaneous Melanoma.

Authors:  Ashley M Holder; Arturas Ziemys
Journal:  Front Oncol       Date:  2020-09-11       Impact factor: 6.244

3.  Locoregional Lymph Node Recurrence of Trunk Melanoma in Non-sentinel Lymph Node Basins: An Observational Retrospective Study.

Authors:  Ruggero Moro; Jessica González-Ramos; Silvestre Martínez-García; Celia Requena; Victor Traves; Esperanza Manrique-Silva; Eduardo Nagore
Journal:  Acta Derm Venereol       Date:  2020-10-06       Impact factor: 3.875

4.  An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumors.

Authors:  Teele Kuusk; Maarten L Donswijk; Renato A Valdés Olmos; Roderick E De Bruijn; Oscar R Brouwer; Kees Hendricksen; Simon Horenblas; Katarzyna Jóźwiak; Warner Prevoo; Henk G Van Der Poel; Bas W G Van Rhijn; Esther M Wit; Axel Bex
Journal:  EJNMMI Res       Date:  2018-12-03       Impact factor: 3.138

Review 5.  PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.

Authors:  Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

6.  Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.

Authors:  Nikki R Adler; Rory Wolfe; Grant A McArthur; John W Kelly; Andrew Haydon; Catriona A McLean; Victoria J Mar
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.